Akili’s new era as a subsidiary of Virtual Therapeutics will start with FDA approval of its digital therapeutic for attention-deficit hyperactivity disorder (ADHD) in adults, a key part of
Treatments emerging from the digital therapeutics space were once greeted with optimism, due to the potential to aid patients’ health through technology, rather than pharmaceuticals.
Digital health company Akili has launched a non-prescription version of its attention-deficit hyperactivity disorder (ADHD) digital therapeutic EndeavorRx, that can be dow
Ensuring that patients remain consistent with their therapies is one of the major challenges facing healthcare, so what if you could make treatment a game?
Akili already has the first and only FDA cleared video game-based digital therapeutic (DTx) for children with attention-deficit hyperactivity disorder (ADHD), but is looking to add to its r